Abstract:BACKGROUND:Tumor heterogeneity may lead to false negative test results for tissue biopsy-based companion diagnostic tests. Real-time polymerase chain reaction (PCR) and digital PCR assays are used to detect rare alleles in cell-free circulating DNA for liquid biopsies; however, those tests lack strong sensitivity at low allele frequencies. We show here a novel real-time digital PCR instrument that utilizes cycle-based amplification curves to further improve the sensitivity and quantification accuracy of digital PCR.METHODS:The novel real-time digital PCR instrument was compared to an endpoint digital PCR system to determine the sensitivity and quantification accuracy of both instruments. Samples were all thermal cycled on the real-time digital PCR instrument but were analyzed on both endpoint and real-time digital PCR instruments to compare the performance without introducing other variables. Contrived samples for epidermal growth factor receptor (EGFR) exon 19 deletion, T790M, and L858R point mutations as well as human epidermal growth factor receptor 2 (HER2) amplification were tested. Different mutant allele frequencies and wildtype to mutant gene copy number ratios were tested for EGFR and HER2, respectively.RESULTS:By removing false positive datapoints using real-time amplification curves, real-time digital PCR improved sensitivity by lowering the baseline for wildtype samples. For EGFR 19del assay, samples with 2 or more fluorescein amidite (FAM) labeled positive wells are determined positive by real-time digital PCR, while a minimum of 5 FAM positive datapoints is needed by endpoint digital PCR. Improved limit of detection for EGFR 19del mutation was also observed. Real-time digital PCR also had better quantification accuracy and sensitivity, resulting in the mutant allele frequencies being closer to the expected values for all EGFR mutations, especially at very low allele frequencies. However, at high allele frequencies or for gene amplification assays, real-time digital PCR is comparable with endpoint digital PCR.CONCLUSIONS:This novel technology with improved sensitivity is important and needed because it addresses current issues with liquid biopsy tests. Due to limited amounts of circulating tumor DNA (ctDNA) obtained for liquid biopsy tests, few copies of mutant alleles are expected. With the lower baseline of real-time digital PCR, false negative test results from tissue biopsy would be more effectively reduced, leading to more patients receiving the targeted therapy they need for better survival.

Robust Dosage PCR (RD‐PCR) for Highly Accurate Dosage Analysis

Robust Dosage-PCR for Detection of Heterozygous Chromosomal Deletions

Recent Advance in Digital PCR

Rare Variants in RPPH1 Real-Time Quantitative PCR Control Assay Binding Sites Result in Incorrect Copy Number Calls

Real-time Digital Polymerase Chain Reaction (PCR) As a Novel Technology Improves Limit of Detection for Rare Allele Assays.

High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number

Digital Droplet PCR for the Absolute Quantification of Exon Skipping Induced by Antisense Oligonucleotides in (Pre-)Clinical Development for Duchenne Muscular Dystrophy

Comparative Study of Three PCR-Based Copy Number Variant Approaches , CFMSA , M-PCR , and MLPA , in 22 Q 11 . 2 Deletion Syndrome

Smartphone-based Mobile Digital PCR Device for DNA Quantitative Analysis with High Accuracy

A Digital PCR Method Based on Highly Specific Taq for Detecting Gene Editing and Mutations

[Reverse transcriptase PCR (RT-PCR) and quantitative-competitive PCR (QC-PCR)]

Optimization of digital droplet polymerase chain reaction for quantification of genetically modified organisms

Digital PCR for the characterization of reference materials

CYP2D6 copy number determination using digital PCR

Cost-effective and robust genotyping using double-mismatch allele-specific quantitative PCR

Evaluation of the impact of single nucleotide polymorphisms and primer mismatches on quantitative PCR

Applications of Digital Polymerase Chain Reaction (dPCR) in Molecular and Clinical Testing

Self-Internal-Reference Probe System for Control-Free Quantification of Mutation Abundance

Droplet Digital PCR for Minimal Residual Disease Quantitation Using Immunoglobulin/T-Cell Receptor Gene Rearrangements in Acute Lymphoblastic Leukemia

DNA detection using recombination proteins

Optimization of duplex digital PCR for the measurement of SARS-CoV-2 RNA